Sinocare Inc
SZSE:300298
Sinocare Inc's latest stock split occurred on Jul 16, 2018
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, Sinocare Inc traded at 22.98 per share. Afterward, the share price was about 17.7043.
The adjusted shares began trading on Jul 16, 2018. This was Sinocare Inc's 6th stock split, following the previous one in May 19, 2017.
1S9
Sinocare Inc
Glance View
Nestled in the heart of China's burgeoning biotech industry, Sinocare Inc. has steadily transformed itself into a powerhouse in the realm of glucose monitoring and diabetes management. Founded in 2002, the company was driven by an urgent need to address the growing epidemic of diabetes in China and beyond. As diabetes continued to exact a heavy toll both economically and medically, Sinocare sought to leverage advanced technological innovations to pioneer user-friendly and affordable monitoring solutions. By placing a firm emphasis on research and development, the company sharpened its expertise in biosensing technology, allowing it to produce a comprehensive range of glucose monitors, test strips, and related healthcare products that cater not just to hospitals but also empower individuals with diabetes to manage their conditions effectively. In its journey, Sinocare smartly diversified beyond simple diagnostics into broader health management solutions. With an eye on increasing the accessibility and functionality of their products, they pursued strategic alliances and acquisitions, notably acquiring Nipro diagnostic business (now Trividia Health) and PTS Diagnostics. These moves helped broaden Sinocare’s horizons to international markets, offering it a stronger footing in the lucrative U.S. and European markets in addition to its dominant Asian presence. Sinocare makes money through the sale of its monitoring devices and the recurring revenue stream generated by test strips and other consumables. Their integrated approach, combining product sales with digital health management services, helps in building a robust ecosystem around its core offerings. This innovative business model not only boosts their bottom line but positions Sinocare as a critical player in the global fight against diabetes, continuously driving towards a future where chronic disease management is much more convenient and effective.
You don't have any saved screeners yet